NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis $47.87 +0.02 (+0.04%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$47.54 -0.34 (-0.70%) As of 10/10/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tourmaline Bio Stock (NASDAQ:TRML) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tourmaline Bio alerts:Sign Up Key Stats Today's Range$47.85▼$47.9050-Day Range$20.72▼$48.1652-Week Range$11.56▼$48.27Volume737,152 shsAverage Volume770,617 shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$45.65Consensus RatingHold Company Overview Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Read More Tourmaline Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreTRML MarketRank™: Tourmaline Bio scored higher than 26% of companies evaluated by MarketBeat, and ranked 821st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingTourmaline Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 9 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Tourmaline Bio is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTourmaline Bio has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tourmaline Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -13.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -13.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tourmaline Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.83% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tourmaline Bio has recently decreased by 38.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.83% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tourmaline Bio has recently decreased by 38.49%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.72 News SentimentTourmaline Bio has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tourmaline Bio this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for TRML on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tourmaline Bio's insider trading history. Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRML Stock News HeadlinesTourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLOctober 6, 2025 | businesswire.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives $45.65 Consensus Price Target from AnalystsOctober 5, 2025 | americanbankingnews.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.October 12 at 2:00 AM | Porter & Company (Ad)Tourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90September 30, 2025 | msn.comNovartis announces commencement of tender offer to acquire Tourmaline BioSeptember 29, 2025 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)September 15, 2025 | prnewswire.comBMO Capital Downgrades Tourmaline Bio (TRML)September 15, 2025 | msn.comTourmaline Bio (TRML): Assessing Valuation as Market Interest GrowsSeptember 14, 2025 | finance.yahoo.comSee More Headlines TRML Stock Analysis - Frequently Asked Questions How have TRML shares performed this year? Tourmaline Bio's stock was trading at $20.28 at the beginning of the year. Since then, TRML stock has increased by 136.0% and is now trading at $47.87. How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.04. How do I buy shares of Tourmaline Bio? Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tourmaline Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings8/13/2025Today10/12/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CIK1827506 WebN/A Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Price Target for Tourmaline Bio$45.65 High Price Target$48.00 Low Price Target$25.00 Potential Upside/Downside-4.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.50% Return on Assets-29.63% Debt Debt-to-Equity RatioN/A Current Ratio24.68 Quick Ratio24.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.71 per share Price / Book4.09Miscellaneous Outstanding Shares25,692,000Free Float22,352,000Market Cap$1.23 billion OptionableOptionable Beta2.27 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TRML) was last updated on 10/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.